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Abstract
Aims/Hypothesis—Insulin activates the insulin receptor (IR) protein tyrosine kinase and 
downstream phosphatidylinositol-3-kinase (PI3K)/Akt signalling in muscle to promote glucose 
uptake. The IR can serve as a substrate for the protein tyrosine phosphatases (PTP) 1B and 
TCPTP, which share a striking 74% sequence identity in their catalytic domains. PTP1B is a 
validated therapeutic target for the alleviation of insulin resistance in type 2 diabetes. PTP1B 
dephosphorylates the IR in liver and muscle to regulate glucose homeostasis, whereas TCPTP 
regulates IR signalling and gluconeogenesis in the liver. In this study we have assessed for the first 
time the role of TCPTP in the regulation of IR signalling in muscle.
Methods—We generated muscle-specific TCPTP-deficient (MCK-Cre;Ptpn2lox/lox) mice and 
assessed the impact on glucose homeostasis and muscle IR signalling in chow versus high fat fed 
mice.
Results—Blood glucose and insulin levels, insulin and glucose tolerances and insulininduced 
muscle IR activation and downstream PI3K/Akt signalling remained unaltered in chow fed MCK-
Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice. In addition, body weight, adiposity, energy expenditure, 
insulin sensitivity and glucose homeostasis were not altered in high fat fed MCK-Cre;Ptpn2lox/lox 
versus Ptpn2lox/lox mice.
#Corresponding author: Tony Tiganis, Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, 
Australia, Tel 61 3 9902 9332, Fax 61 3 9902 9500, Tony.Tiganis@med.monash.edu.au.
S.G. current address: St. Vincent’s Institute, Victoria 3065, Australia
B.J.W. current address: Heart Research Institute, Camperdown NSW 2050, Australia
Duality of Interest: Zhong-Yin Zhang is a co-founder of Aarden Pharmaceuticals and Chairman of its scientific advisory board. 
There is no other duality of interest associated with this manuscript.
Author contributions: T.L.M., S.G., B.J.W, S.Z., Z.-Y.Z. contributed to the design of experiments and/or interpretation of data and 
provided intellectual input; K.L., M.J.W and B.G.N helped design experiments and/or interpreted data and contributed to the drafting 
and revision of the article; T. T. conceived and designed the study, interpreted data and drafted and revised the manuscript.
HHS Public Access
Author manuscript
Diabetologia. Author manuscript; available in PMC 2016 October 11.
Published in final edited form as:
Diabetologia. 2012 February ; 55(2): 468–478. doi:10.1007/s00125-011-2386-z.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions—These results indicate that TCPTP deficiency in muscle has no effect on insulin 
signalling and glucose homeostasis and does not prevent the development of high fat diet-induced 
insulin resistance. Thus, despite their high degree of sequence identity, PTP1B and TCPTP 
differentially contribute to IR regulation in muscle. Our results are consistent with these two 
highly related PTPs having distinct contributions to IR regulation in different tissues.
Keywords
Diabetes; glucose homeostasis; insulin resistance; insulin signalling; muscle; protein tyrosine 
phosphatase; PTP; PTP1B; TCPTP
INTRODUCTION
Type 2, or non-insulin-dependent diabetes accounts for 90–95% of cases of diabetes and is 
characterized by insulin resistance and hyperglycemia. Insulin resistance manifests as 
diminished insulin responsiveness in insulin’s key target tissues including liver, fat and 
muscle and is associated with aging, obesity and a sedentary lifestyle [1, 2]. Insulin is 
secreted by the pancreas in response to an increase in blood glucose levels and suppresses 
glucose production in the liver whilst promoting glucose uptake into muscle and adipose 
tissue. Insulin exerts its effects by binding to the insulin receptor (IR) on the surface of cells. 
Binding of insulin activates the protein tyrosine kinase (PTK) activity of the intracellular β-
subunit, resulting in autophosphorylation and the phosphorylation of substrates such as 
insulin receptor substrate (IRS)-1 [1, 3, 4]. Phosphotyrosyl residues on IRS-1 serve as 
docking sites for the recruitment of SH2 domain-containing proteins; these include the 
adaptor protein Grb-2 and the p85 regulatory subunit of phosphatidylinositol-3-kinase 
(PI3K), which activate the Ras/Mitogen-activated protein kinase (MAPK) and PI3K/Akt 
cascades to elicit the metabolic and mitogenic actions of insulin [1, 3, 4]. In particular, PI3K 
signalling and Akt2 are essential for the translocation/docking of the GLUT4 glucose 
transporter on the plasma membrane in muscle and fat [1, 2, 5–7]. Although the precise 
molecular mechanism(s) that underlie the development of insulin resistance remain unclear, 
one widely accepted mechanism involves the impairment of PI3K recruitment to IRS-1 [1, 
2]. Hence, strategies that enhance IR activation and downstream signalling may be effective 
in alleviating insulin resistance.
Protein tyrosine phosphatases (PTPs) [8, 9] are key regulators of IR signalling, 
dephosphorylating and inactivating the IR within minutes of stimulation [10]. The prototypic 
family member PTP1B (encoded by PTPN1) dephosphorylates the IR β subunit Y1162/
Y1163 activation loop autophosphorylation site to attenuate insulin signalling in vivo [11–
16]. Mice with a global deficiency in PTP1B (Ptpn1−/−) exhibit enhanced insulin sensitivity, 
associated with increased IR activation and downstream IRS-1 tyrosine phosphorylation in 
liver and muscle [12–16]. PTP1B’s direct contribution to IR regulation in muscle has been 
substantiated by the generation of muscle-specific PTP1B deficient (MCK-Cre;Ptpn1lox/lox) 
mice [16]. MCK-Cre; Ptpn1lox/lox mice exhibit improved insulin sensitivity and glucose 
tolerance associated with elevated muscle IR activation and signalling [16]. Moreover, 
MCK-Cre; Ptpn1lox/lox mice are protected from the development of insulin resistance 
induced by a high fat diet [16]. Conversely, overexpression of PTP1B in muscle causes 
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insulin resistance [17] and PTP1B expression and/or activity may be increased in muscle 
and adipose tissue of insulin-resistant humans and rodents [18–23]. PTP1B’s prominent role 
in IR regulation and glucose homeostasis has engendered considerable interest from the 
pharmaceutical industry for the development of PTP1B inhibitors for the treatment of type 2 
diabetes [22, 24–26].
Several other tyrosine-specific PTPs have also been implicated in the attenuation of insulin 
signalling in muscle. Like PTP1B, LAR (Leukocyte common antigen–related) PTP 
expression may be increased in muscle from insulin-resistant rodents/humans and transgenic 
overexpression of LAR in muscle suppresses insulin signalling and glucose uptake and 
promotes whole body insulin resistance [18, 19, 27–30]. Recent studies have also shown that 
IR activation and signalling are elevated in PTPε-deficient differentiated myoblasts, but its 
role in glucose homeostasis in vivo remains unknown [31].
Previously, we showed that the IR can also serve as a bona fide substrate for the phosphatase 
TCPTP (encoded by PTPN2) [8, 11, 32, 33]. In particular, we reported that IR activation and 
signalling were enhanced in TCPTP-deficient fibroblasts and in HepG2 hepatoma cells after 
TCPTP knockdown [32, 33]. Moreover, we reported that TCPTP knockdown in PTP1B-
deficient MEFS further enhanced IR activation, consistent with the two PTPs acting in a 
coordinated manner to attenuate insulin signalling [11]. PTP1B and TCPTP are also 
similarly oxidised by reactive oxygen species in fibroblasts in response to insulin [33]. The 
concerted oxidation of PTP1B and TCPTP suggests that both enzymes coordinately 
attenuate IR signalling [9, 34, 35]. Finally, we have shown that TCPTP may also regulate 
insulin signalling and glucose homeostasis in vivo [36]. We reported that insulin signalling 
was elevated in hepatocytes isolated from TCPTP heterozygous mice (Ptpn2+/−) and that 
high fat fed Ptpn2+/− mice were protected from the development of hyperglycemia [36]. The 
prevention of hyperglycemia in high fat fed Ptpn2+/− mice could be attributed to decreased 
hepatic gluconeogenesis and glucose production associated with enhanced STAT3 
phosphorylation, as well as prolonged hepatic insulin-induced PI3K/Akt signalling [36]. 
Previous studies have shown that PTP1B-deficiency in liver also enhances IR activation and 
the insulin-induced suppression of hepatic glucose production [37]. Thus, the combinatorial 
inhibition of PTP1B and TCPTP in liver might represent an effective strategy for the 
prevention of fasting hyperglycemia in patients with type 2 diabetes.
Skeletal muscle accounts for the majority of glucose disposal following a meal and insulin 
resistance in muscle is an early event in the pathogenesis of type 2 diabetes. Therefore, the 
inhibition of PTPs such as PTP1B that attenuate IR activation and signalling might be 
particularly effective in alleviating insulin resistance. Given the established potential for 
PTP1B and TCPTP to act together in the attenuation of IR signalling in fibroblasts and 
hepatocytes [32, 33, 36], we asked whether TCPTP might also regulate the insulin response 
and glucose homeostasis in muscle.
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METHODS
Antibodies and reagents
Human insulin was from Sigma-Aldrich (St Louis, MO, USA) and the rat insulin RIA kit 
from Linco Research (St Charles, MO, USA). Rabbit α-phospho-Y1162/1163-IR from 
Biosource International (Camarillo, CA, USA), α-phospho-S473-Akt, α–phospho-Y705-
STAT3 and α-Akt and mouse α-STAT3 were from Cell Signaling (Beverly, MA, USA). 
Mouse α-IR β subunit from Santa Cruz (Santa Cruz, CA, USA), α-tubulin (Ab-5) from 
Sigma-Aldrich (St Louis, MO, USA) and α-TCPTP (6F3) from Medimabs (Montréal, 
Québec, Canada).
Mice
We maintained mice on a 12 h light-dark cycle in a temperature-controlled high barrier 
facility (ARL, Monash University, Victoria, Australia) with free access to food and water 
according to NHMRC Australian Code of Practice for the Care and Use of Animals. MCK-
Cre mice have been described previously [16] and have been backcrossed onto the C57BL/6 
background for 6 generations. A detail description of the construct design and the generation 
of Ptpn2lox/+ mice will be provided elsewhere [38]. Briefly, the targeting construct 
incorporated loxP sites flanking exons 5 and 6 and a neomycin-resistance cassette flanked 
by FRT sites. The linearised construct was electroporated into Bruce 4 (C57BL/6J) ES cells 
and G418 resistant colonies identified by Southern blot analysis. Correctly targeted clones 
were injected into BALB/c blastocysts. High percentage male chimeras were mated with 
C57BL/6J mice to produce Ptpn2lox/+ offspring and then bred with FLPe mice (C57BL/6) to 
excise the neomycin-resistance cassette. We used aged-matched and sex-matched mice for 
all experiments. Mice were fed a standard chow (19% protein, 4.6% fat and 4.8% crude 
fibre) or a high fat diet (23% fat; 45% of total energy from fat; SF04-027; Specialty Feeds, 
Glen Forest, WA, Australia) as indicated.
Metabolic measurements
Insulin and glucose tolerance tests were performed as described previously [39]. Fed and 
fasted blood were collected by retro-orbital bleeding and blood glucose plasma insulin levels 
determined as described previously [39]. To measure oxygen consumption and energy 
expenditure, food intake and ambulatory activity mice were acclimated for 24 h and then 
monitored for 48 h in an environmentally controlled Comprehensive Lab Animal Monitoring 
System (Columbus Instruments, Columbus, OH, USA) fitted with indirect open circuit 
calorimetry and food consumption and activity monitors. Respiratory exchange ratios 
(VCO2/VO2) were calculated from the gas exchange data. Data were averaged for 2 dark and 
two light cycles.
2-Deoxy-D-glucose uptake assay
Soleus muscles dissected from 8 week old mice were incubated in oxygenated (95% O2/5% 
CO2) Krebs-Henseleit buffer supplemented with 0.1% BSA, 8 mmol/l mannitol, 2 mmol/l 
pyruvate plus 10 µmol/l 2-deoxy-D-glucose for 20 min and 2-deoxy-D-[1,2 3H]-glucose 
(1.85 × 104 Bq/ml; GE Healthcare, Mount Prospect, IL, USA) uptake determined for 10 min 
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in the presence or absence of 10 nmol/l insulin (Actrapid, Nova Nordisk, Bagsværd, 
Denmark) as described previously [40, 41].
Cell culture
Primary mouse myoblasts were isolated from the muscle of 2–4 week old mice and cultured 
in Ham’s F10 medium containing 20% (v/v) heat inactivated FBS, antibiotics [100 U/ml 
penicillin and 100 µg/ml streptomycin] and 2.5 ng/ml human basic FGF as described 
previously [39]. Mouse myoblasts were differentiated into multinucleated myotubes in DME 
medium containing 5% (v/v) horse serum (Sigma-Aldrich, MO, USA) plus antibiotics for 5 
days and then serum-starved for 6 h and stimulated with insulin. Rat L6 myoblasts (ATCC) 
were cultured in DME containing 20% (v/v) heat inactivated FBS plus antibiotics. Where 
indicated L6 myoblasts were serum starved for 4 h, pre-incubated with PTP1B inhibitor 
[compound II; [42]] and/or TCPTP inhibitor [compound 8; [43]] for 1 h and then stimulated 
with 1 nmol/l insulin.
Biochemical analyses
Mouse tissues were dissected and immediately frozen in liquid N2. Tissues were 
homogenized in 10–20 volumes of ice cold RIPA lysis buffer and clarified by 
centrifugatBenjaminion as described previously [39]. Cells were lysed in RIPA buffer and 
clarified by centrifugation (16,000 × g for 5 min at 4°C). Tissue and cell lysates were 
resolved by SDS-PAGE, transferred onto Immobilon-P transfer membrane (Millipore, 
Billerica, MA, USA) and immunoblotted as described previously [44]. Lox/lox and MTKO 
tissue and cell lysates, or cells treated with vehicle control or inhibitor, were resolved on the 
same SDS-PAGE gel, or otherwise transferred onto the same transfer membrane for 
immunoblotting and development.
Statistical Analyses
All data were presented as mean ± SEM and statistical significance determined using the 
Student’s t test, or repeated-measures 2-way ANOVA. A p value of less than 0.05 was 
considered significant.
RESULTS
Generation and characterisation of mice with a muscle-specific deletion of TCPTP
To ask if TCPTP has a role in the regulation of insulin receptor signalling in muscle, we 
generated a floxed allele of Ptpn2 (loxP sites flanking exons 5 and 6) by gene targeting in 
Bruce 4 (C57BL/6J) embryonic stem cells. Ptpn2lox/lox (C57BL/6) mice were crossed with 
mice expressing the Cre recombinase under the control of the muscle creatine kinase 
promoter (MCK-Cre; C57Bl/6) to excise Ptpn2 in muscle. TCPTP expression, as determined 
by immunoblot analysis, was deleted in the gastrocnemius and soleus muscles of the MCK-
Cre;Ptpn2lox/lox mice, but not in other insulin responsive tissues such as liver, fat and 
hypothalamus (Fig. 1a).
At 8 weeks of age, no differences in body weight were noted between MCK-Cre; 
Ptpn2lox/lox and Ptpn2lox/lox male mice (Fig. 1b). Consistent with this, corresponding tissue 
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weights, including gastrocnemius muscle, were similar in both groups (Fig. 1c). No overt 
differences in muscle development or glycogen content (as assessed by hematoxylin & eosin 
and periodic acid-schiff staining) were evident in MCK-Cre;Ptpn2lox/lox mice (Fig. 1d). 
Oxygen consumption, energy expenditure (as assessed by indirect calorimetry) and 
respiratory exchange ratios (RER; a measure of fat and carbohydrate utilisation) were 
unaltered between MCK-Cre;Ptpn2lox/lox and Ptpn2lox/lox male mice, suggesting that TCPTP 
deficiency in muscle had no impact on whole body energy homeostasis and fuel utilisation 
(Fig. 1e). Moreover, ambulatory activity was not affected in mice lacking TCPTP in muscle 
when compared with Ptpn2lox/lox littermates (Fig. 1e).
Insulin sensitivity and glucose homeostasis are not altered in muscle-specific TCPTP-
deficient mice
To investigate whether TCPTP deficiency in muscle improves insulin sensitivity and whole 
body glucose clearance, we performed insulin tolerance tests (ITTs) and glucose tolerance 
tests (GTTs) in 8 week-old MCK-Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice. No differences 
in ITTs (Fig. 2a) or GTTs (Fig. 2b) were evident in MCK-Cre;Ptpn2lox/lox versus 
Ptpn2lox/lox mice. Consistent with these results we found no significant differences in fed 
and fasted blood glucose levels, or fed and fasted plasma insulin levels in MCK-
Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice (Fig. 2c). In addition, no differences were evident 
in the uptake of 2-deoxy-D glucose uptake into MCK-Cre;Ptpn2lox/lox versus Ptpn2lox/lox 
soleus muscle ex vivo in response to insulin (Fig. 2d). These results indicate that muscle-
specific TCPTP-deficiency in chow-fed lean mice does not alter insulin sensitivity and 
glucose homeostasis.
Insulin signalling is not altered by TCPTP-deficiency in muscle
Next, we determined whether TCPTP deficiency alters insulin signalling in muscle (Fig. 3). 
First, we determined whether IR activation and signalling were altered by TCPTP deficiency 
in gastrocnemius muscle after bolus insulin administration (1 mU/g, 10 min; 
intraperitoneal). IR activation and downstream PI3K/Akt signalling were assessed by 
immunoblot analysis using antibodies to the IR β-subunit Y1162/Y1163 and Akt Ser-473 
phosphorylation sites respectively. No differences in basal or insulin-induced IR activation 
and PI3K/Akt signalling were evident in muscle in vivo (Fig. 3a). Second, we isolated 
myoblasts from MCK-Cre; Ptpn2lox/lox versus Ptpn2lox/lox mice and assessed insulin-
induced signalling in the corresponding differentiated myotubes (Fig. 3b); the differentiation 
of myoblasts into myotubes, as assessed by the expression of MyoD and myogenin, was 
unaltered by TCPTP-deficiency (data not shown). We found that insulin (1–10 nmol/l)-
induced signalling (0–30 min), as assessed by Akt Ser-473 phosphorylation, was not altered 
by TCPTP-deficiency in myotubes in vitro (Fig. 3b; data not shown). Taken together, these 
results indicate that TCPTP-deficiency does not alter insulin signalling in muscle.
Body weight and glucose homeostasis are not altered in high fat fed (HFF) muscle-specific 
TCPTP-deficient mice
Although insulin sensitivity was unaltered in chow fed MCK-Cre;Ptpn2lox/lox mice, it is 
possible that differences might only be evident when mice are fed a high fat diet to render 
them insulin resistant. For example, mice with a muscle-specific deficiency in PTEN, a PTP 
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superfamily member with lipid phosphatase activity that attenuates PI3K signalling, do not 
exhibit any overt differences in insulin sensitivity unless challenged with a high fat diet [9, 
45]. Therefore, we next examined whether muscle-specific TCPTP deficiency could enhance 
insulin sensitivity and prevent high fat diet-induced weight gain and the development of 
insulin resistance. 8–10 week-old MCK-Cre;Ptpn2lox/lox and Ptpn2lox/lox male mice were 
fed either a normal chow (4.6% fat) or a high fat (23% fat) diet for 12 weeks. No differences 
in weight gain or adiposity were evident in either chow fed or high fat fed (HFF) MCK-
Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice (Fig. 4a–d). Similarly no differences in oxygen 
consumption, energy expenditure or fuel utilisation (RER) were noted in HFF MCK-
Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice (Fig. 4e; data not shown). There was a trend for 
lower ambulatory activity in HFF MCK-Cre;Ptpn2lox/lox mice (Fig. 4e), but this was not 
statistically significant (p=0.11).
To determine whether muscle-specific TCPTP deficiency could attenuate the development of 
high fat diet-induced insulin resistance we performed insulin and glucose tolerances tests. 
No significant differences in insulin sensitivity or glucose tolerance were observed in 8 
week-old MCK-Cre;Ptpn2lox/lox versus Ptpn2lox/lox male mice that were fed a chow or a 
high fat diet for 12 weeks (Fig. 5a and b). In addition, fed and fasted blood glucose levels 
were similar between MCK-Cre;Ptpn2lox/lox and Ptpn2lox/lox mice on either diet (Fig. 5c and 
d). Moreover, fed and fasted plasma insulin levels were unaltered in HFF MCK-
Cre;Ptpn2lox/lox versus Ptpn2lox/lox mice (Fig. 5e). Finally, insulin-induced muscle Akt 
Ser-473 phosphorylation was not different in HFF MCK-Cre;Ptpn2lox/lox versus Ptpn2lox/lox 
mice (Fig. 5f). Taken together, these results indicate that TCPTP deficiency in muscle has no 
overt effect on insulin signalling and glucose homeostasis and does not prevent the 
development of insulin resistance associated with high fat feeding.
TCPTP and PTP1B are not redundant in insulin signalling
The unaltered insulin signalling in TCPTP deficient muscle might be due to a functional 
redundancy with PTP1B. To explore this possibility we asked whether the combined 
inhibition of TCPTP and PTP1B in muscle cells might result in synergistic or additive 
effects on insulin signalling (Fig. 6a). To inhibit TCPTP and/or PTP1B we took advantage of 
the highly selective inhibitors compound 8 (Ki for TCPTP of 4.3 nmol/l; [43]) and 
compound II (Ki for PTP1B of 26 nmol/l; [46]) respectively. Consistent with previous 
studies implicating PTP1B in the regulation of insulin signalling in muscle [11–16], we that 
found PTP1B, but not TCPTP inhibition enhanced insulin-induced PI3K/Akt signalling in 
rat L6 myoblasts (Fig. 6a and b). TCPTP inhibition with compound 8 resulted in increased 
phosphorylation of STAT3 (Fig. 6c), a bona fide TCPTP substrate [8, 36]. However, no 
additive effects on insulin signalling (as assessed by Akt Ser-473 phosphorylation) were 
evident in L6 cells when both PTP1B and TCPTP were inhibited (Fig. 6a). Therefore these 
results indicate that TCPTP does not regulate insulin-induced PI3K/Akt signalling in muscle 
cells, even when PTP1B is inhibited.
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DISCUSSION
Although we have shown previously that the IR can serve as a substrate for TCPTP [8, 11, 
32, 33, 36], in this study we report that TCPTP is redundant in IR signalling in muscle. In 
contrast to PTP1B deficiency, which enhances insulin signalling and glucose uptake in 
muscle and protects mice from the development of insulin resistance [12, 13, 16], we found 
that TCPTP-deficiency in muscle had no overt effect on glucose homeostasis.
The catalytic domains of PTP1B and TCPTP share a high degree of primary (72% identity; 
86% similarity) and tertiary structural similarity and have similar active sites. In particular, 
both PTPs have a second phosphotyrosine-binding pocket that allows for the selective 
recognition of tandem phosphorylated substrates [47, 48] such as the IR PTK [11, 32, 47, 
49], JAK PTKs (JAK1-3 and TYK2) [49] and the MET receptor PTK [50]. However despite 
their similarity, TCPTP and PTP1B exhibit a high degree of substrate selectivity. For 
example, PTP1B can dephosphorylate JAK2, but not JAK1/3, whereas TCPTP 
dephosphorylates JAK1/3, but not JAK2 [49, 51, 52]. These differences in PTP1B versus 
TCPTP substrate selectivity are associated with inherent differences in PTP catalytic domain 
substrate specificity, as well as differences in tissue distribution and subcellular localisation. 
PTP1B is ubiquitous, whereas TCPTP is most abundant in the hematopoietic compartment 
[8]. Moreover, PTP1B is targeted to the endoplasmic reticulum by a hydrophobic C–
terminus, whereas TCPTP is expressed as two variants, with one being targeted to the 
endoplasmic reticulum and the other to the nucleus [8]; both TCPTP variants are expressed 
in muscle [36].
In keeping with the two phosphatases exhibiting differences in substrate specificity, we have 
shown previously that PTP1B and TCPTP can function cooperatively in the same cell to 
regulate the intensity and duration of IR activation and signalling [11, 32, 33]. Similarly, 
PTP1B and TCPTP work in concert to regulate MET receptor phosphorylation [50] and 
PTP1B and TCPTP regulate STAT6 phosphorylation in the cytoplasm and nucleus 
respectively [53]. Thus, PTP1B and TCPTP can function in a coordinated manner for the 
temporal and spatial control of cellular signalling. Both TCPTP [36] and PTP1B [37] appear 
to be required for IR regulation in the liver. In other studies, we have shown that chow-fed 
liver-specific TCPTP-deficient mice exhibit enhanced glucose homeostasis (unpublished 
observation). So why then might TCPTP be redundant in IR activation and signalling in 
muscle? On possibility is that relative TCPTP expression might be decreased and/or PTP1B 
expression increased in muscle, but this does not appear to be the case [36], [37]; indeed 
PTP1B levels are lower in muscle when compared to liver [37]. Moreover, we have shown in 
this study that TCPTP-deficiency does not enhance insulin signalling even when PTP1B is 
inhibited, arguing against a functional redundancy due to the presence of PTP1B.
The evidence for PTP1B regulating IR activation and signalling in muscle is compelling [12, 
13, 16]. In particular, insulin sensitivity is increased in chow fed muscle-specific PTP1B 
knockout mice and muscle IR and IRS-1 phosphorylation are elevated in the fasted state 
[16]. Consistent with this, our studies indicate that PTP1B inhibition in muscle cells can 
enhance insulin signalling. However, recent studies have indicated that PTP1B, but not 
TCPTP may affect the endosomal sorting of activated receptor PTKs through the 
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dephosphorylation of proteins such as STAM2 [54, 55]. Therefore, one possibility is that the 
effects of PTP1B on insulin signalling may be indirect and attributable to altered endosomal 
sorting of the IR. In this case, PTPs other than PTP1B and TCPTP may be responsible for 
the direct dephosphorylation of the IR in response to insulin. One candidate may be PTPε, 
which translocates to the IR in response to insulin [31]. Another candidate is SHP-1, the 
global deletion of which results in a dramatic improvement in insulin sensitivity and glucose 
tolerance and a significant enhancement in insulin-induced IR and IRS phosphorylation in 
muscle [56].
The inhibition of PTP1B for the enhancement of insulin responsiveness and the alleviation 
of insulin resistance remains a rational therapeutic approach for the treatment of type 2 
diabetes [24, 25]. However, PTP1B inhibitors in preclinical development also variably 
inhibit TCPTP [24, 25]. One question that has arisen from our previous work has been 
whether the inadvertent inhibition of TCPTP by PTP1B inhibitors in muscle might 
contribute to the enhancement of insulin sensitivity; our current studies suggest that this is 
unlikely. Additional studies are required to determine if TCPTP has a role in other insulin 
responsive tissues such as fat, where PTP1B may be redundant in regulating the insulin 
response [13, 14].
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Abbreviations
GTT Glucose tolerance test
HFF High fat fed
IR insulin receptor
IRS insulin receptor substrate
ITT insulin tolerance test
LAR leukocyte common antigen–related
MAPK mitogen-activated protein kinase
(PI3K) phosphatidylinositol-3-kinase
PTK protein tyrosine kinase
PTP protein tyrosine phosphatase
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Figure 1. Generation and characterisation of muscle-specific TCPTP-knockout mice
(a) TCPTP protein levels in Ptpn2lox/lox control (lox/lox) and MCK-Cre; Ptpn2lox/lox 
muscle-specific TCPTP knockout (MTKO) mice as determined by immunoblotting. (b) 
Body weights in 8 week-old male lox/lox and MTKO mice. (c) Tissue weights in 8–10 
week-old male lox/lox and MTKO mice. (d) Gastrocnemius and soleus muscle from lox/lox 
and MTKO mice were isolated and processed for histology (hematoxylin & eosin and 
periodic acid-schiff). (e) Oxygen consumption, energy expenditure and respiratory exchange 
ratios in the light and dark cycles in 8–10 week-old lox/lox and MTKO mice were 
determined by indirect calorimetry. Ambulatory activity (x and z axes) was also determined. 
Results shown are mean ± SE. ***p<0.001 for light cycle versus dark cycle. Black bars, lox/
lox, n=7; white bars, MTKO, n=7.
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Figure 2. Glucose homeostasis in MTKO mice
(a) 8–10 week-old lox/lox and MTKO male mice were fasted and insulin tolerance tests 
(ITTs; 0.5 insulin mU/g body weight) or (b) glucose tolerance tests (GTTs; 1 mg glucose/g 
body weight) performed. Areas under ITT or GTT curves were determined. (c) Fed and 
fasted blood glucose and plasma insulin levels in 8–10 week-old lox/lox and MTKO male 
mice were determined. (d) 2-Deoxy-D-[3H]-glucose uptake assays of control and insulin-
stimulated soleus explant from lox/lox and MTKO mice. Results shown are means ± SE.. 
*p<0.05 and ***p<0.001 for fed versus fasted. Black bars, lox/lox, n=7; white bars, MTKO, 
n=7.
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Figure 3. Insulin signalling in MTKO mice and muscle cells
(a) 8–10 week-old lox/lox and MTKO male mice were fasted for 4 h and injected with saline 
or insulin (1 mU/g, 10 min; IP) and gastrocnemius muscle extracted and processed for 
immunoblot analysis with antibodies to the phosphorylated (Y1162/Y1163) and activated IR 
β subunit (p-IR) and Ser-473 phosphorylated Akt (p-Akt) and then total IR and Akt. (b) 
Myoblasts from lox/lox and MTKO mice were differentiated, serum starved and stimulated 
with 1 nM insulin and processed for immunoblot analysis as indicated. Results shown in a–b 
are representative of three independent experiments.
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Figure 4. Body weight, adiposity and energy homeostasis in MTKO mice
8–10 week-old male lox/lox and MTKO male mice were either (a) fed a normal chow diet 
(n=6 per genotype), or (b) high fat fed (HFF; n=7 per genotype) for 12 weeks and weekly 
body weights measured. Tissue weights in (c) chow fed (n=6 per genotype) and (d) HFF 
(n=7 per genotype) lox/lox and MTKO mice. (e) Oxygen consumption, energy expenditure, 
respiratory exchange ratios and ambulatory activity were determined in HFF lox/lox and 
MTKO mice (n=6 per genotype). Results shown in a–d are means ± SE. **p<0.01 and 
***p<0.001 for light cycle versus dark cycle. Black bars/squares, lox/lox; white bars/
squares, MTKO.
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Figure 5. Glucose homeostasis in MTKO mice fed a high fat diet
8–10 week-old male lox/lox and MTKO male mice were fed either a normal chow diet or 
HFF for 12 weeks. (a) Mice were fasted and insulin tolerance tests (ITTs; 0.75 insulin mU/g 
body weight) or (b) glucose tolerance tests (GTTs; 2 mg glucose/g body weight) were 
performed. Areas under ITT or GTT curves were determined (n=7 per genotype). (c–d) Fed 
and fasted blood glucose levels in chow fed (n=6 per genotype) and HFF (n=7 per genotype) 
lox/lox and MTKO male mice. (e) Fed and fasted plasma insulin levels in HFF lox/lox and 
MTKO male mice (n=7 per genotype). (f) HFF mice were fasted for 4 h and injected with 
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saline or insulin (1 mU/g; IP) and gastrocnemius muscle extracted and processed for 
immunoblot analysis with antibodies to p-Akt, Akt and tubulin. Results shown are means ± 
SE. *p<0.05, **p<0.01 and ***p<0.001 for fed versus fasted. Black bars/squares, lox/lox; 
white bars/squares, MTKO.
Loh et al. Page 18
Diabetologia. Author manuscript; available in PMC 2016 October 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. PTP1B but not TCPTP inhibition in muscle cells enhances insulin signalling
(a–b) L6 myoblasts were serum starved and pre-incubated with 10–50 nmol/l compound 8 
(TCPTP inhibitor), 100 nmol/l compound II (PTP1B inhibitor), or both for 1 h and then 
stimulated with 1 nmol/l insulin for the indicated times and processed for immunoblot 
analysis antibodies to p-Akt, Akt and tubulin. (c) L6 cells were pretreated with vehicle 
control of 10 nmol/l compound 8 and stimulated with 10 ng/ml IL-6 for the indicated time 
and processed for immunoblot analysis with antibodies to p-STAT3 and STAT3. Results 
shown in a–c are representative of three independent experiments.
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